China (govt)–Agilent: grant, 201909– Thought Leader Award to Hualiang Jiang at SIMM CAS for work in medicinal chemistry + drug discovery

	Period	2019-09-19
	Region	Shanghai
	Country	China
	Money taker	Shanghai Institute of Materia Medica (SIMM CAS)
	Group	China (govt)
	Money source	Agilent Technologies Inc. (NYSE: A)
	Product	medicinal chemistry
	Product 2	drug discovery
	Person	Jiang, Hualiang (China (govt) 201909 Professor at Shanghain Institute of Materia Medica at CAS)

Agilent Technologies Inc.. (9/19/19). "Press Release: Agilent Presents Thought Leader Award to Professor Hualiang Jiang". Santa Clara, CA.

Chinese Academy of Sciences scientist recognized for his work in medicinal chemistry and drug discovery

Agilent Technologies Inc. (NYSE: A) announced today that Professor Hualiang Jiang has received an Agilent Thought Leader Award. Professor Jiang directs the Shanghai Institute of Materia Medica at the Chinese Academy of Sciences and is a leading researcher in the area of medicinal chemistry and computational drug design.

Professor Jiang has a strong track record identifying new targets for cancer therapy and designing inhibitors that block protein-protein interactions. He and his collaborators designed the first inhibitor of Atox1/CCS and used it to prove that copper chaperones are potential new targets for anticancer therapies. They also designed the first inhibitor of speckle-type POZ protein for potential application to clear-cell renal cell carcinoma.

The Agilent Thought Leader Award will support Professor Jiang in his latest research using novel glycoside-based small molecules to test the potential benefits of an alternative class of inhibitors of the PD-L1/PD-1pathway. His laboratory will measure and compare the metabolic and pharmacologic effects of the small molecule inhibitors against that of benchmark therapeutic PD-L1 antibodies.

"Agilent's support for leading researchers like Professor Jiang underscores our commitment to accelerating the development of metabolomics and integrated biology workflows for cancer drug discovery and characterization," said Victor Chan, Agilent vice president, and general manager of Laboratory Solutions for Agilent Greater China.

"It is my great honor to receive an Agilent Thought Leader Award. As a drug designer, I am interested in discovering novel drug candidates from natural products, in particular, natural carbohydrate compounds, against new drug targets," said Professor Jiang. "Computational drug design and chemical proteomics are the major tools in my research platform. My research team will benefit from the integration of metabolomics data."

The Agilent Thought Leader Award program promotes fundamental scientific advances by contributing financial support, products, and expertise to the research of influential thought leaders in the life sciences, diagnostics, and chemical analysis space. Further information is available at the Agilent Thought Leader Award web page.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenues of $4.91 billion in fiscal 2018 and employs 15,550 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to our Newsroom.

Follow Agilent on LinkedIn, Twitter, and Facebook.

Contact

Naomi Goumillout
Agilent Technologies
+1 781 266 2819
naomi.goumillout@agilent.com